Combined halofenate-chlorpropamide was evaluated for the treatment of NIDDM. Four subjects treated with 500 mg/day chlorpropamide were given 500–1000 mg halofenate daily for 48 wk or longer. Fasting plasma glucose fell from 210 ± 16 (± SEM) (11.67 ± 0.89 mM) to 107 ± 10 mg/dl (± SEM) (5.94 ± 0.55 mM), P < 0.005. Twelve additional subjects were entered into a 16-wk double-blind study testing chlorpropamide plus either placebo or halofenate. In the halofenate group, the mean fasting glucose fell from 227 ± 27 (± SEM) (12.61 ± 1.50 mM) and reached 107 ± 19 mg/dl (± SEM) (5.94 ± 1.06 mM) during the fourth month, whereas the placebo groups showed a decrease from 242 ± 22 (± SEM) to 208 ± 29 mg/dl (± SEM) (P < 0.005). In addition, halofenate reduced the height of postprandial glycemic excursions by lowering fasting plasma glucose. When halofenate was used as the only therapy, reduction in fasting plasma glucose was small [179 ± 12 reduced to 142 ± 8 mg/dl (± SEM); 9.94 ± 0.67 mM and 7.89 ± 0.44 mM], P < 0.05.

This content is only available via PDF.